Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult3. fázis

An open-label study to evaluate the effect of crinecerfont on androgen reduction and related outcomes in adults with classic CAH

A legfontosabb adatok

Ki végzi
Neurocrine Biosciences Inc.
Hol
Ausztria, Bulgária, Csehország, Németország, Olaszország, Portugália, Románia, Spanyolország és Svédország23 helyszín, 9 országbanVálassz országot a helyszínekhez
Állapot
Toborzás még nem indult
Fázis
3. fázis
Résztvevők
75 fő, tervezett
Kezdés
2026. aug. 14.
Várható befejezés
2028. ápr. 27.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. november 2.

Ki vehet részt

Életkor
18 év – 64 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Completed informed consent
  • CCI
  • All participants must be ≥18 years of age . Female participants must also be ≤45 years of age
  • CCI. Female participants must have AMH ≥1 ng/mL and FSH <25 mIU/mL at screening
  • Have a medically confirmed diagnosis of classic 21-OHD CAH based on standard medically accepted criteria such as elevated 17-OHP level, confirmed CYP21A2 genotype, positive newborn screening with confirmatory second-tier testing, or cosyntropin stimulation
  • Have androstenedione CCI (prior to morning GC dose) at screening
  • Be on a GC dose regimen CCI HCe that has been stable for at least 1 month prior to screening; consists of 1 or more of the following orally administered GCs: hydrocortisone (including modified- or sustained-release hydrocortisone), prednisone, prednisolone, or methylprednisolone; and includes a morning dose of GC
  • If treated with fludrocortisone, dose should be stable for at least 1 month prior to screening with an upright PRA during screening that is not greater than ULN on the participant’s usual sodium intake. If PRA is >ULN, the participant must have systolic blood pressure >100 mmHg, without orthostatic hypotension, and with serum sodium and potassium in the normal range
  • Participants with ovaries of childbearing potential must agree to use contraception consistently from screening until 30 days after the last dose of study treatment or final study visit, whichever is longer. Acceptable methods of contraception are required for participants with ovaries: • Bilateral salpingectomy or bilateral tubal occlusion • Intrauterine device or intrauterine hormone-releasing system. • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, which may be oral, intravaginal, or transdermal, initiated at least 3 months prior to screening. • Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injected, or implanted initiated at least 3 months prior to screening. • Total abstinence from sexual intercourse (periodic abstinence is not acceptable). • Sexual partner(s) who had been vasectomized at least 3 months prior to screening with successful procedure. • Progesterone only where inhibition of ovulation is not the primary mode of action. • Male or female condom with or without spermicide. • Cap, diaphragm or sponge with spermicide
  • CCI

Ki nem vehet részt

  • Used any active investigational drug in the context of a clinical trial within 30 days or 5 half-lives (whichever is longer) before screening or plans to use such an investigational drug (other than the study drug) during the study
  • Have previously received a CRF1 antagonist, including crinecerfont, within 1 year before screening
  • Using any prohibited concomitant medication and cannot discontinue use of these medications for the duration of the study
  • Have current substance dependence or substance or alcohol abuse (drugs including controlled substance or non-prescribed use of prescription drugs; nicotine and caffeine dependence are not exclusionary)
  • Have a significant risk of suicidal or violent behavior. Participants with any suicidal ideation of type 4 (active suicidal ideation with some intent to act, without specific plan) or type 5 (active suicidal ideation with specific plan and intent) in the past 6 months before screening or any history of suicidal behavior within the past year based on the C-SSRS should be excluded
  • Have had a blood loss ≥550 mL or donated blood or blood products within 8 weeks before Day 1
  • Have received dexamethasone for chronic use in the 6 months before screening
  • At increased risk of developing adrenal crisis in the investigator’s opinion, based on, for example, repeated history of adrenal crisis in the past, prior history of adrenal crisis precipitated by reducing GC dose, recent episode(s), etc
  • Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic therapy with oral GCs, or requiring chronic therapy with inhaled GCs that based on dose and hormone profile the investigator deems would yield significant systemic exposure interfering with study endpoints
  • Have a clinically significant medical condition or chronic disease (including history of neurological, hepatic, renal, cardiovascular, GI, significant malabsorption, hematologic, pulmonary, psychiatric, or endocrine disease [excluding CAH]) that in the opinion of the investigator would preclude the participant from participating in and completing the study or that could confound interpretation of study outcomes
  • History of malignancy, unless successfully treated with curative intent and considered to be cured
  • Known sensitivity (ie, hypersensitivity) or allergy to any corticotropin-releasing hormone (CRH) receptor antagonist or to any component of the study treatment
  • Have evidence of chronic renal or liver disease based on any of these screening laboratory test abnormalities: • eGFRCr (CKD-EPI, 2021) <45ml/min per 1.73 m2. • AST >3 × ULN. • ALT >3 × ULN. • Total bilirubin >1.5 × ULN unless due to a documented diagnosis of Gilbert's syndrome
  • Have absolute neutrophil count <1.0 × 103/mm3at screening
  • Pregnant (ie, positive pregnancy test at screening or Day 1) or lactating, or plans to become pregnant during the study
  • CCI
  • CCI
  • Have had hysterectomy or oophorectomy
  • CCI
  • Have a known or suspected diagnosis of any of the other forms of classic CAH including 11-β-hydroxylase deficiency, 17-α-hydroxylase deficiency, 3-β-hydroxysteroid dehydrogenase deficiency, P450 side-chain cleavage deficiency, or P450 oxidoreductase deficiency
  • In the investigator’s opinion, the participant is not capable of adhering to the protocol requirements
  • CCI

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 64 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

9 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the effect of crinecerfont on elevated androstenedione levels in adults with classic CAH on a stable GC dose for at least 6 months.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
Illeszkedési kérdések
Forrás: 2025-524282-24-00: ki vehet részt
A regiszteradat frissítve
2026. november 2.